Investment Rating - The investment rating for the company is "Buy" (maintained) with a target price of 10.75 CNY per share [1][5]. Core Views - The report highlights that the aramid business is steadily growing, while the spandex segment is under pressure due to ongoing supply-demand imbalances and price competition [4][9]. - The company has adjusted its profit forecasts for 2025-2027, with expected net profits of 222 million, 292 million, and 361 million CNY respectively, reflecting a significant downward revision from previous estimates [5][9]. Financial Performance Summary - The company reported a revenue of 3,925 million CNY in 2023, with a slight increase to 3,929 million CNY in 2024, and projected revenues of 4,494 million CNY in 2025, 4,938 million CNY in 2026, and 5,359 million CNY in 2027, indicating a growth rate of 14.4% in 2025 [7][12]. - The net profit attributable to the parent company is expected to recover from 90 million CNY in 2024 to 222 million CNY in 2025, showing a year-on-year growth of 147.9% [5][12]. - The gross margin is projected to improve from 16.0% in 2024 to 21.4% in 2027, while the net margin is expected to rise from 2.3% in 2024 to 6.7% in 2027 [7][12]. Segment Analysis - The spandex segment is facing challenges with a projected gross margin of -11.86% in 2024, leading to further losses [9]. - The aramid segment is expected to maintain a growth trajectory, with a 13% increase in sales volume in 2024 despite a decline in revenue and gross profit due to intensified price competition [9]. - The company is advancing its aramid-coated diaphragm industrialization process, with pilot projects already in production and full-scale production expected to commence in 2025 [9].
泰和新材(002254):氨纶景气承压,静待底部反转